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In elderly population sepsis is one of the leading causes of intensive care unit (ICU)
admissions in the United States. Sepsis-induced delirium (SID) is the most frequent
cause of delirium in ICU (Martin et al., 2010). Together delirium and SID represent
under-recognized public health problems which place an increasing financial burden on
the US health care system, currently estimated at 143–152 billion dollars per year (Leslie
et al., 2008). The interest in SID was recently reignited as it was demonstrated that,
contrary to prior beliefs, cognitive deficits induced by this condition may be irreversible
and lead to dementia (Pandharipande et al., 2013; Brummel et al., 2014). Conversely, it
is construed that diagnosing SID early or mitigating its full blown manifestations may
preempt geriatric cognitive disorders. Biological markers specific for sepsis and SID
would facilitate the development of potential therapies, monitor the disease process and
at the same time enable elderly individuals to make better informed decisions regarding
surgeries which may pose the risk of complications, including sepsis and delirium. This
article proposes a battery of peripheral blood markers to be used for diagnostic and
prognostic purposes in sepsis and SID. Though each individual marker may not be
specific enough, we believe that together as a battery they may achieve the necessary
accuracy to answer two important questions: who may be vulnerable to the development
of sepsis, and who may develop SID and irreversible cognitive deficits following sepsis?
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INTRODUCTION
At present there are no biological markers to indicate vulnerability to sepsis or to the
CNS dysfunction following it. Electroencephalography (EEG) and various instruments such as
Confusion Assessment Method (CAM), Delirium Rating Scale (DRS) or Delirium Symptoms
Interview (DSI) are currently used for diagnosing delirium, however they are not specific for SID
and difficult to perform in sedated or intubated ICU patients (Zampieri et al., 2011). Recent studies
have shown that delirium in general and SID in particular are unrecognized by clinicians in 32–
66% of cases and because of their resemblance to psychiatric conditions, patients with delirium are
frequently admitted to psychiatric wards, thus delaying much needed interventions (Leslie et al.,
2008; Reeves et al., 2010). In order to avoid this problem the Society for Academic Emergency
Medicine Geriatrics Task Force designated delirium screening a key quality indicator in elderly
care (Terrell et al., 2009).
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In our prior work in SID and delirium, we emphasized a
potential epigenomic screening tool, the microRNA-6775 (miR-
6775), which can be obtained from peripheral blood exosomes.
This miR seems to block the transcription of CHRNA 7
gene which codes for alpha 7 nicotinic cholinergic receptors,
while at the same time augments the expression of RNF-
128, the Gene Related to Anergia in Lymphocytes (GRAIL),
a gene involved in sepsis associated immune suppression
(SAIS). Since SAIS represents a major cause of death in sepsis
patients, miR-6775 may be a sepsis-stage marker in addition
to a being a SID vulnerability screening tool (Sfera et al.,
2014). We have hypothesized that delirium predisposing factors
including low grade inflammation and the paucity of alpha 7
nicotinic acetylcholine receptors (nAChRs) may be the result
of dysfunctional miR-6775 which silences the gene coding for
these receptors. If this hypothesis is correct, miR-6775 may
emerge as a marker of vulnerability to both sepsis and SID.
In addition to epigenomic markers we drew attention to an
astrocytic proteomic marker, the aquaporin-4 (AQP-4) protein
which was found to be up-regulated in delirium (Sfera and
Osorio, 2015).
In the present article, instead of focusing on individual
biomarkers, we present a proteomic battery consisting of
molecules released by the innate immune system, the initiator
of septic responses. These markers can be obtained from the
peripheral blood exosomes, a platform which carries to the
periphery the molecular fingerprints of cells located in various
tissues including the brain.
FROM THE IMMUNOLOGICAL TO THE
NEUROLOGICAL SYNAPSE:
PATHOPHYSIOLOGY OF SEPSIS AND SID
Critical care physicians have known for a long time that 70–
80% of patients diagnosed with severe sepsis had been admitted
to the hospital for reasons other than infections (Munford and
Suffredini, 2010). Indeed, infection is necessary for a septic
response, but not sufficient, as most infections remain localized
and the inflammation does not spread throughout the body
tissues. Moreover, sepsis-like global inflammatory responses are
known to occur in burns, trauma or pancreatitis in the absence of
infection (Balk, 2014).
Sepsis is thought to be ignited by a failure of the
innate immune system to turn “off” after initiating an initial
inflammatory response to intruding pathogens. The innate
immunity “on” and “off” switch is located at the immunological
synapse, the nanoscale junction between the T lymphocytes
and the antigen presenting cells (APCs). This junction is
populated by pattern recognition receptors (PRR) out of
which the toll-like receptors (TLRs) are the best known.
Activation of TLRs by pathogen toxins triggers “cytokine
storms,” release of non-specific pro-inflammatory molecules.
Switching “off” the innate immune system is epigenomically
controlled by microRNAs action on TLRs (Bayarsaihan, 2011;
Stearns-Kurosawa et al., 2011). Turning the innate immunity
“off” must occur when the more specific adaptive immune
system comes “on line.” Sepsis may be triggered by defective
microRNAs which may be incapable of deactivating the
TLRs and turn the innate immunity “off.” In this scenario,
both the adaptive and the innate immunity continue to
work in parallel, eventually leading to immune exhaustion or
SAIS.
MicroRNAs or miRs are short, 18–22 nucleotides in
length, non-coding RNAs which have the ability to silence
gene expression by inhibiting or degrading their messenger
RNAs (mRNA). MicroRNAs were shown to modulate multiple
biological processes, but those of interest for sepsis and SID
include activation/deactivation of the innate immune system,
cytoskeletal rearrangements in the innate immune cells (which
enable cellular proliferation), and modulation of astrocytic
volume (by changes in membrane permeability).
The CNS-immune interaction was demonstrated to be
mediated by transmigration of peripheral lymphocytes and
microphages through the blood-brain-barrier (BBB) and via the
recently described lymphatic vessels in the dura mater (Louveau
et al., 2015). The discovery of CNS lymphatics suddenly changed
the perspective on the peripheral-central immune cooperation
into a holistic one in which astrocytes, microglia and peripheral
macrophages work in an innate immune continuum (Sternberg,
2006; Louveau et al., 2015). For example, the peripheral dendritic
cells (DC) immigrate into the CNS and function as antigen
presenting cells (APCs), while the activated microglia emigrate
from the brain to the periphery, transporting inflammation
(Sfera et al., 2014; Sfera and Osorio, 2015). These findings
provide an explanation for the previously observed impairment
in peripheral immunity following CNS pathology such as
strokes, neurosurgical interventions, Alzheimer’s disease (AD)
and schizophrenia (Hochmeister et al., 2008; D’Agostino et al.,
2012).
In the CNS, astrocytes and microglia are full members of the
innate immune system which respond to peripheral infections by
adopting a reactive stance (reactive gliosis). For example, reactive
astrocytes undergo hypertrophy (edema) probably in an attempt
to erect an additional physical barrier and restrict the spread of
infection (Majewska and Szczepanik, 2006). Astrocytic swelling
due to aquaporin-4 (AQP-4) up-regulation was documented in
SID and may explain why most known delirium biomarkers are
released by astrocytes (Papadopoulos and Verkman, 2013; Sfera
et al., 2014; Thrane et al., 2014).
It is reasonable to assume that astrocytic swelling
(astroedema) along with hypocholinergia (due to silenced
CHRNA 7 gene) activate the TLRs, engendering low grade
inflammation which is considered a delirium vulnerability
marker in elderly (Court et al., 2001; Mitsis et al., 2009).
For example, in post-operative delirium activation of TLR-4
(expressed by microglia and astrocytes) was demonstrated (Jalleh
et al., 2012; Sofroniew, 2015). MicroRNA-130a is known to
reduce astroedema by silencing the transcription of AQP-4
proteins (Sepramaniam et al., 2012). Moreover, miR-132 was
demonstrated to restore CNS cholinergic signaling (Shaked
et al., 2009). These epigenomic markers may represent a CNS
compensatory response to astroedema and damaged cholinergic
signaling.
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PROTEOMIC BIOMARKERS OF SID
Aquaporin-4 (AQP-4) proteins in astrocytic end-feet constitute
specific markers for astroedema described in SID. Exosomes
carrying AQP-4 proteins from astrocytes to the peripheral blood
may be utilized as biomarkers and therapeutic targets especially
in SAIS (Papadopoulos and Verkman, 2013; Thrane et al., 2014;
Sfera and Osorio, 2015).
Galectin-9 (Gal-9) and its receptor, the T cell immunoglobulin
mucin-3 (Tim-3) expressed on T lymphocytes was shown to
inhibit Th-17 proliferation both in vitro and in vivo (Oomizu
et al., 2012). Gal-9 was demonstrated to play a major role in cell
cycle regulation as it was shown to inhibit the cell cycle arrest in
the G1 phase, promoting cellular proliferation. A dysfunctional
Gal-9 may explain the aberrant neuronal cell cycle re-entry
documented in AD as well as the exaggerated proliferation of
macrophages and T-cells in the early phase of sepsis (Currais
et al., 2009). In the CNS, Gal-9 is secreted by astrocytes and
it was demonstrated to affect the astrocyte-microglia dialog
(Steelman and Li, 2014). Interestingly, microRNA-155 (which
modulates TLRs at the immunologic synapse) acts on the Tim-3
receptors, competing with Gal-9 (Cheng et al., 2015). Therefore,
a significant drop in miR-155 level and/or an increase in Gal-9
level may suggest immune restoration in sepsis.
CRYAB (alphaB-crystallin) is a small heat-shock protein which
was demonstrated to reduce T cell proliferation (including
the CD-69 response). Animal studies show that Cryab-
/- mice present with higher Th-17 cell count and more
intense neuroinflammation, compared to wild-type counterparts
(Arac et al., 2011). In the brain Cryab is secreted by
astrocytes as an anti-inflammatory molecule; its presence in
peripheral blood exosomes may indicate functional astrocytes,
reflecting epigenetic integrity. CRYAB is involved in the
process of microRNA maturation; its absence may result in
dysfunctional microRNAs, including miR-6775, miR-155, miR-
132, and miR-130 family. A drop in the level of this marker
in peripheral blood exosomes may reflect the body-wide
inflammation of sepsis with the imminent potential for SID onset
(Ousman et al., 2007).
Ubiquitin-modifying protein A 20 has potent anti-
inflammatory and anti-proliferative properties. For example it
can decrease T cell differentiation into the neurotoxic Th-17
phenotype (Kool et al., 2011). Animal studies demonstrate that
A 20 deficiency causes spontaneous neuroinflammation with
reactive gliosis. In addition, it was demonstrated that that the
A 20 protein deactivates the innate immunity at the level of the
TLRs in the immunological synapse (Boone et al., 2004). Absence
of TLR deactivation was demonstrated to result in exaggerated
inflammatory responses, the “cytokine storms” characteristic of
early sepsis. Micro RNA-155 epigenetically modulates the “on”
and “off” activation of TLRs, suggesting involvement in sepsis
and SID (O’Neill et al., 2011; Table 1). A drop in A 20 level along
with an increase in miR-155 levels are markers of poor prognosis
in sepsis and SID.
Vimentin is a major constituent of the cellular cytoskeleton
which was found to orchestrate the Th-17 and possibly cancer
cells migration into the CNS (Nieminen et al., 2006). Indeed, in
sepsis an elevated Th-17 count was reported as vimentin equips
TABLE 1 | Potential proteomic markers for sepsis and SID.
Protein Action Effect




Galectin-9 -Inhibits Th-17 proliferation Beneficial for sepsis/SID




A 20 protein -Deactivates TLRs
-Turns innate immunity “off ”
Beneficial in sepsis/SID
Vimentin -Enables cytoskeleton for motility and
proliferation
Detrimental in sepsis/SID
T lymphocytes with both the motility and the amoeboid shape
necessary for transmigration across the blood-brain-barrier
(Nieminen et al., 2006). By rearranging the cytoskeleton vimentin
facilitates proliferation of CD-69 lymphocyte in response to
mitogens; this response can be measured by the lymphocyte
proliferation test (LPT) (Nieminen et al., 2006;Ward et al., 2008).
LPT is currently being used as a peripheral blood marker for
AD and traumatic brain injury (TBI), based on the observation
that lymphocytes derived from patients with AD present with
a proliferation defect, a lower CD-69 count after mitogenic
stimulation, compared to lymphocytes derived from normal
individuals (Zhang et al., 2013). In fact the transition between
elevated and depressed CD-69 response, may mark the precise
point in time when a localized infection transitions to sepsis
and SID. This transition may be captured by the stimulation
index (SI) which represents the ratio of CD-69 expression
level/endogenous CD-69 level. The SI may mirror the onset and
progression of immune suppression and if obtained daily in ICU
patients may detect sepsis onset. At the epigenetic level the CD-
69 vimentin-induced response is modulated by miR-155 and
miR-130 family, again rendering these miRs epigenetic markers
for SID.
EPIGENOMIC BIOMARKERS OF SID
Approximately 60% of known miRs are expressed in the brain,
rendering them almost ideal peripheral biomarkers for many
CNS disorders (Song and Lee, 2015). Exosome-isolated miRs
provide a higher diagnostic precision than miRs obtained from
plasma (Stenvang et al., 2012).
MicroRNA-6775: silences the transcription of CHRNA-7
gene which codes for alpha 7 nicotinic acetylcholine receptors
(nAChRs). When silenced CHRNA-7 gene augments the
proliferation of Th-17 lymphocytes. Another action of
microRNA-6775 involves activation of RNA-128, the gene
related to anergia in lymphocytes (GRAIL), predisposing to SAIS
(Sfera et al., 2014).
MicroRNA-130 family: nicknamed astromiRs, this miR family
are modulators of cellular motility (Tu et al., 2014). Members of
this family include:
MicroRNA–130b: promotes metastatic cancer aggressiveness
by augmenting vimentin-induced cytoskeletal changes.
MicroRNA-130b is believed to be an oncomiR as it augments
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TABLE 2 | Potential epigenomic markers of sepsis and SID.
MicroRNA Action Effect





miR-130 a -Silences transcription of AQP-4
gene
-Decreases cell motility and





miR-130b -Increases cell motility and
proliferation
miR-155 -Increases CD-69 response
-Activated TLRs by binding to
galectin-9 receptor






malignant aggression by enhancing cellular ability to migrate.
We however characterize miR-130b as a motilimiR since
metastasizing is occurs secondary to increased cellular motility.
By the same mechanism miR-130b may promote Th-17
transmigration into the CNS (Table 1). For this reason miR-130b
can be considered both a therapeutic target and a biomarker of
SID (Leavy, 2010).
MicroRNA-130a (miR-130a): may also be a therapeutic target
in addition to being a SID biomarker This miR, silences
the transcription of AQP-4 proteins in astrocytic end-feet,
reducing astroedema and neuroinflammation (Sepramaniam
et al., 2012). In addition, miR-130a inhibits cellular locomotion
and proliferation and is being credited with inhibition of
metastatic spread. Since its action opposesmiR-130b, we consider
it an antimiR to 130a (Murugaiyan et al., 2011).
MicroRNA-155 (miR-155): In sepsis, a dysregulated miR-
155 was shown to unleash inflammation via activation of
TLRs preventing deactivation of the innate immune system
upon activation of adaptive immunity. Others have shown
that silencing miR-155 may be beneficial in experimental
autoimmune encephalomyelitis (Murugaiyan et al., 2011), AD
(Song and Lee, 2015), and other neuropsychiatric disorders (Hu
et al., 2013). We believe that miR-155 is a plausible therapeutic
target in SID in addition of being of diagnostic and prognostic
benefit.
MicroRNA-132: acts as a natural cholinesterase inhibitor (also
called a cholinomiR) as it enhances cholinergic signaling by
inhibiting its degrading enzymes (Shaked et al., 2009; Nadorp
and Soreq, 2014) (Table 2). Deficient acetylcholine is one of the
best documented hypotheses of delirium. Daily levels of miR-132
obtained from peripheral blood exosomes in ICU patients with
SID may reflect the prognostic trend.
TINY BUBBLES: AN EXOSOMAL
TRANSPORTATION PLATFORM
Extracellular vesicles are tiny membrane structures which are
divided by their size, into ectosomes, larger vesicles (over
100 nm), and exosomes, smaller vesicles (50–100 nm). They
are released by a wide variety of cells including immune,
CNS and cancer cells. Their cargo consists of proteins, DNA,
microRNAs, and mRNAs which carry the signatures of their cells
of origin throughout the body fluids. After release from their
source, miRs circulate with the peripheral blood either bound to
lipoproteins or incorporated in exosomes which offer protection
from dilution and the ambient ribonuclease (Wagner et al., 2013).
Therefore, assays of exosome-packaged miRs derived from the
peripheral blood are more reliable compared to assays of non-
exosomal miRs (Cheng et al., 2014). Exosome content can be
analyzed with the help of simple commercial exosome isolation
kits or by more complex ultracentrifugation (Corrado et al.,
2013).
At the immunological synapse, exosomes carry pathogen-
derived molecules between the T cell and the APC, committing
T cells to particular phenotypes (Schorey et al., 2015). In sepsis it
was demonstrated that naïve T cells differentiate into neurotoxic
Th-17 lymphocytes (Martinez et al., 2008). We believe that this
metamorphosis is enabled by the disinhibition of RNF-128 gene
by dysfunctional miR-6775 which, probably acts on vimentin to
enable transformation of naïve T cells into the highly mobile and
aggressive Th-17 phenotype.
In the CNS, exosomes were demonstrated to be involved
in neurotransmitter signaling at neurological synapses (Chivet
et al., 2014; Glebov et al., 2015). For example, exosomal miRs
in the prefrontal cortex synapses were recently demonstrated
in schizophrenia and bipolar disorder (Banigan et al., 2013).
In SID exosome-analysis may identify stage-of-disease markers
and treatment targets. For example, astrocytes were shown to
release exosomes containing miR-155 and miR-130 family which
along with AQP-4 proteins which constitute SID biomarkers.
Indeed the National Institute of Health recently awarded a grant
for studying blood exosomes containing astrocytic proteins as
diagnostic markers for CNS disorders (Crocker and Vella, 2015).
In AD neural proteins such as amyloid beta, total tau and P-tau
were recently isolated from peripheral blood exosomes (Fiandaca
et al., 2015).
Exosomes were demonstrated capable of carry aquaporin
proteins to the body periphery. For example, urinary exosomes
containing aquaporin-1 (AQP-1) proteins are currently being
utilized in nephrology as novel biomarkers of renal ischemia and
reperfusion (Sonoda et al., 2009). In SID, the up-regulated AQP-
4 proteins originating in astrocytic end-feet may be detectable in
peripheral blood exosomes.
CONCLUSIONS
Sepsis and SID represent health care problems which translate
into a major economic burden likely to increase along with
the demographics of aging population. Biological markers with
adequate sensitivity and specificity for SID could decrease
not only the length of hospital stay, lead to new treatments,
but also preempt the epidemic of irreversible cognitive deficit
and dementia in elderly. With the same token the ability to
predict vulnerability to delirium and subsequent dementia would
facilitate the informed consent process of elderly individuals
deciding for elective surgeries.
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